PHAXIAM announces the availability of the preparatory documents  for the Combined General Meeting of 28 June 2024

News & events

Tout News Press release
Press release
PHAXIAM announces the availability of the preparatory documents  for the Combined General Meeting of 28 June 2024

Shareholders of PHAXIAM are invited to attend the Combined General Meeting to be held on 28 June 2024 at 9:30 a.m. at the Company’s registered office at 60 avenue Rockefeller – 69008 Lyon (France).

Read more
Press release
PHAXIAM provides Business and Financial Update for the First Quarter of 2024

Webinar (in French) today, May 15, 2024, at 6.00 pm CEST

Read more
News
PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus

Read more
Press release
Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024

Read more
News
PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD) 

Read more
Press release
PHAXIAM Therapeutics announces 2023 Full-Year Results and Provides Business Update

Conference call and webcast (English) on Thursday, March 21, 2024 at 9:30am ET / 2:30pm CET

Read more
Press release
PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

PHAXIAM today announces that the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Capital Market (“Nasdaq”) has become effective

Read more
Press release
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market

Read more
News
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024

As of December 31, 2023, PHAXIAM Therapeutics had cash and cash equivalents totaling €10.5 million (approximately $11.6 million).

Read more
Press release
PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023

Conference call and webcast (English) on Wednesday, November 15, 2023at 8:30am ET / 2:30pm CET

Read more
News
PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus

Read more
Press release
PHAXIAM announced that TP ICAP Midcap, a brokerage firm and investment bank specializing in small and mid-caps has initiated coverage of its shares

TP ICAP Midcap began covering the stock with a “Buy” recommendation and valued the Company at €8.5 per share

Read more

Contact
our team

Journalist, investor, healthcare professional, partner or candidate... if you have any questions about PHAXIAM, please do not hesitate to contact our teams.

Contact us